Health
Canopy Biosciences develops spatial proteomics assay for COVID-19 – News-Medical.Net
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19. The assay uses high-plex spatial proteomics and is performed on Canopy’s ZellScannerONE precise spatial phenotyping instrument. ZellScannerONE enables multiplexed spatial quantification of protein biomarkers in tissue samples, as well as in suspended cells. Relative to traditional techniques, such as flow cytometry, Canopy’s ChipCytometry is able to detect and…
-
General24 hours agoAlbanese and Dutton go head-to-head in debate rematch
-
Noosa News24 hours agoQueensland cop cleared by court of stealing watches during anti-gang raid
-
Noosa News24 hours agoEaster weather forecast: What to expect in Sydney, Perth, Melbourne, Brisbane, Adelaide and Canberra
-
Noosa News14 hours agoIncrease in extreme weather events poses ‘substantial risk’ to blood supplies, researchers warn